Vyome Holdings reports FY25 revenue $319.7k vs $246.9k last year

“Vyome is targeting one of the biggest challenges in the world today – inflammation. So many of our medical and mental problems are linked to increased inflammation. We are building our business with a laser focus on shareholder value, whether it’s our capital structure or the development of our assets,” said Krishna Gupta, Chairman of Vyome. “We had a great first fiscal year completion as a public company, thanks to our unique strengths, including expertise in/access to the US-India innovation corridor.”